Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress.1
強生公司（紐約證券交易所代碼：JNJ）今天公佈了1b/2期Origami-1期研究的新數據，該數據顯示，Rybrevant（amivantamab-vmjw）聯合化療（mfolfox6 [FOLFOX] 或FOLFIRI）在沒有化療的RAS/BRAF野生型（WT）轉移性結直腸癌（mCRC）患者中顯示出快速、持久的抗腫瘤活性之前接受過抗表皮生長因子受體（EGFR）治療。這些數據是在2024年歐洲腫瘤內科學會（ESMO）大會上的小型口頭報告中公佈的。1